Severe relapses of cutaneous T‐cell lymphoma after treatment of chronic graft‐versus‐host disease with ruxolitinib

Cohen, Elisabeth; Bozonnat, Alizée; Battistella, Maxime; Calvani, Julien; Vignon‐Pennamen, Marie‐Dominique; Rivet, Jacqueline; Moins‐Teisserenc, Hélène; Ta, Van‐Anh; Ram‐Wolff, Caroline; Bouaziz, Jean‐David; Mahevas, Thibault; Bagot, Martine; Mourah, Samia; Louveau, Baptiste; Sicre de Fontbrune, Flore; Peffault de Latour, Regis; de Masson, Adèle; Battesti, Gilles

doi:10.1111/jdv.19408

Cited by 1 publication

(3 citation statements)

References 11 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cohen et al [ 52 ] presented two cases of CTCL worsening after receiving ruxolitinib (a JAK1 and 2 inhibitor) for chronic GVHD treatment. One was a man in his 60s, with T3N0M0B0 MF and large-cell transformation’ histological evidence.…”

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…However, besides studies describing positive effects after the use of JAK inhibitors in CTCL patients, there are also several reports on the de novo development of CTCL [ 49 , 50 , 51 , 52 ]. To our knowledge, a total of five cases have been reported, of which, three cases took multiple medications to treat arthritis [ 49 , 50 , 51 ], and two cases received GVHD treatment following allo-SCT [ 52 ]. Since all patients were receiving immunosuppressive medications, it seems that immunosuppression for a long time before taking JAK inhibitors may play a role in increasing the risk of CTCL incidents or relapse.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature

Vahabi,

Bahramian,

Esmaeili

et al. 2024

Cancers

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCLs) are a group of lymphoid neoplasms with high relapse rates and no curative treatment other than allogeneic stem cell transplantation (allo-SCT). CTCL is significantly influenced by disruption of JAK/STAT signaling. Therefore, Janus kinase (JAK) inhibitors may be promising for CTCL treatment. This study is a systematic review aiming to investigate the role of JAK inhibitors in the treatment of CTCL, including their efficacy and safety. Out of 438 initially searched articles, we present 13 eligible ones. The overall response rate (ORR) in the treatment with JAK inhibitors in clinical trials was 11–35%, although different subtypes of CTCL showed different ORRs. Mycosis fungoides showed an ORR of 14–45%, while subcutaneous-panniculitis-like T-cell lymphoma (SPTCL) displayed an ORR ranging from 75% to 100%. Five cases were reported having a relapse/incident of CTCL after using JAK inhibitors; of these, three cases were de novo CTCLs in patients under treatment with a JAK inhibitor due to refractory arthritis, and two cases were relapsed disease after graft-versus-host disease treatment following allo-SCT. In conclusion, using JAK inhibitors for CTCL treatment seems promising with acceptable side effects, especially in patients with SPTCL. Some biomarkers, like pS6, showed an association with better responses. Caution should be taken when treating patients with an underlying autoimmune disease and prior immunosuppression.

show abstract

Section: Resultsmentioning

confidence: 99%